Interní Med. 2008; 10(7): 327-332
New options of treatment of chronic viral hepatitis
- Klinika infekčních chorob, FN Brno
Chronic hepatitis B and C are in a worldwide scale the most frequent causes of liver cirrhosis and hepatocellular carcinoma causing significant mortality. The treatment of chronic viral hepatitis has been recently quickly developing. New medications against hepatitis B virus (HBV) continue to be introduced in clinical practice and efficacy and safety of many other medications is being tested in clinical trials of various phases. Standard treatment of chronic infection with hepatitis C virus (HCV) is still the combination of pegylated interferon alpha and ribavirin. New ways how to make use of the therapeutic potential of these medications the most effectively are being searched for. Based on analysis of initial parameters concerning the virus and the patient and also monitoring of viral kinetics during the initial phase of treatment the necessary length of treatment is adjusted to fit an individual patient.
Keywords: Key words: viral hepatitis, pegylated interferon alfa, standard interferon alfa, adefovir dipivoxil, entecavir, telbivudine, ribavirin.
Published: October 1, 2008 Show citation
References
- Davis GL, Wong JB, McHutchison JG, et al. Early virology response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
Go to original source... 
Go to PubMed... - Ferenci P, Fried M, Schiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433. Go to original source... Go to PubMed...
- Husa P. Virové hepatitidy. 1. vyd. Praha: Galén; 2005.
- Husa P, Plíšek S, Šperl J, Urbánek P (koordinátoři), Galský J, Hůlek P, Kümpel P, Němeček V, Volfová M (abecedně). Diagnostika a léčba chronické hepatitidy B. Doporučený postup ČHS a SIL ČLS JEP. 1) Vnitř Lék 2007; 53: s. 1221-1230. 2) Klin Mikrobiol Inf Lék 2008; 14: 35-43.
- Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology. 2006; 130: 632-638. Go to original source... Go to PubMed...
- Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897. Go to original source... Go to PubMed...
- Lok ASF, McMahon BJ. Chronic hepatitis B. AASLD Practice Guidelines. Hepatology 2007; 45: 507-539. Go to original source... Go to PubMed...
- Marcellin P. Hepatitis C and hepatitis B in 2007. In: Marcellin P, editor. Management of patients with viral hepatitis. Paris: APHC 2007: 7-23.
- Pawlotsky JM, Dusheiko G, Hatzakis, et al. Virologic monitoring of hepatitis B therapy in clinical trials and practice: recommendation for a standardized approach. Gastroenterology 2008; 134: 405-415. Go to original source... Go to PubMed...
- Strader DFB, Wright T, Thomas DL, Seeff L. Diagnosis, management, and treatment of hepatitis C. AASLD Practice Guideline. Hepatology 2004; 39: 1147-1171. Go to original source... Go to PubMed...
- Urbánek P. Infekce virem hepatitidy C. 1. vyd. Praha: Galén; 2004.
- Urbánek P, Husa P, Galský J, Šperl J, (koordinátoři), Kümpel P, Němeček V, Plíšek S, Volfová M (v abecedním pořadí). Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Doporučený postup České hepatologické společnosti a Společnosti infekčního lékařství ČLS JEP. Datum vydání doporučení 18. března 2008. Dostupné na www.ceskahepatologie.cz a www.infekce.cz.